Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) $ in Millions			3 Months Ended		4 Months Ended	36 Months Ended
		Sep. 03, 2015	Apr. 03, 2016 USD ($) site	Mar. 29, 2015 USD ($)	Dec. 31, 2015 USD ($)	Sep. 03, 2018 USD ($)
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			$ 2,500
Percentage of non-cash restructuring charges expected			25.00%
Total costs associated with acquisitions and cost-reduction/productivity initiatives			$ 228
Restructuring charges:
Employee terminations	[1]		24	$ 31
Asset impairments	[1]		1	6
Exit costs	[1]		4	6
Total restructuring charges	[1]		30	42
Transaction costs	[2]		24	5
Integration costs	[3]		87	13
Restructuring charges and certain acquisition-related costs	[4]		141	60
Total additional depreciation––asset restructuring	[5]		49	18
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[6]		62	48
Total costs associated with acquisitions and cost-reduction/productivity initiatives			252	127
Cost of Sales [Member]
Restructuring charges:
Total additional depreciation––asset restructuring	[5]		45	17
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[6]		43	13
Selling, Informational and Administrative Expenses [Member]
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[6]		12	26
Research and Development Expense [Member]
Restructuring charges:
Total additional depreciation––asset restructuring	[5]		4	1
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[6]		$ 6	$ 8
Manufacturing Plant Network Rationalization And Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Expected number of sites exited | site			4
Acquisition-related Costs [Member] | Manufacturing Plant Network Rationalization And Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			$ 400
Restructuring costs incurred			357
Facility Closing [Member] | Manufacturing Plant Network Rationalization And Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			1,000
Restructuring costs incurred			570
Business Restructuring Reserves [Member] | Global Commercial Structure Reorganization [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			225
Restructuring costs incurred			219
Commercial Real Estate [Member] | Other Cost Reduction / Productivity Initiatives [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			850
Restructuring costs incurred			$ 532
Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Expected integration related costs, period		3 years
Hospira [Member] | Return of Acquired Rights [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost incurred					$ 215
Forecast [Member] | Hospira [Member]
Restructuring charges:
Integration costs						$ 1,000

[1] In the three months ended April 3, 2016, Employee terminations represent the expected reduction of the workforce by approximately 100 employees, mainly in manufacturing. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.The restructuring charges for the three months ended April 3, 2016 are associated with the following:•the Global Innovative Pharmaceutical segment (GIP) ($8 million); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($1 million); the Global Established Pharmaceutical segment (GEP) ($3 million); Worldwide Research and Development and Medical (WRD/M) ($3 million); manufacturing operations ($14 million); and Corporate ($1 million).The restructuring charges for the three months ended March 29, 2015 are associated with the following:•GIP ($12 million); VOC ($13 million); GEP ($10 million); WRD/M ($12 million); manufacturing operations ($22 million income); and Corporate ($18 million).

[2] Transaction costs represent external costs for banking, legal, accounting and other similar services, most of which are directly related to the terminated transaction with Allergan.

[3] Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes, primarily related to the acquisition of Hospira.

[4] Amounts may not add due to rounding.

[5] Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

[6] Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.